Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

Obesity and its metabolic consequences are a major public health concern worldwide. Obesity is associated with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance. Cannabinoid-1 receptor (CB₁R) antagonists reduce body weight and improve cardiometabolic abnormalities in experimental and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects. Here we have demonstrated that a CB₁R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB₁R in the brains of mice with genetic or diet-induced obesity, but it does cause weight-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile. These effects were due to blockade of CB₁R in peripheral tissues, including the liver, as verified through the use of CB₁R-deficient mice with or without transgenic expression of CB₁R in the liver. These results suggest that targeting peripheral CB₁R has therapeutic potential for alleviating cardiometabolic risk in obese patients.

Endocannabinoids are endogenous lipid mediators that interact with the same G protein–coupled receptors — CB₁R and CB₂R — that recognize plant-derived cannabinoids, and they regulate a broad range of physiological functions. CB₁Rs are expressed at very high levels in the brain but are also present at much lower yet functionally relevant concentrations in various peripheral tissues, whereas the expression of CB₂Rs is largely limited to cells of the immune and hematopoietic systems. Activation of CB₁R results in increased appetite, insulin resistance, and increased hepatic lipogenesis, which suggests the involvement of the endocannabinoid/CB₁R system in obesity and its metabolic consequences (1). Indeed, obesity and its metabolic complications are characterized by an overactive endocannabinoid system (2–5), and chronic treatment with CB₁R antagonists leads to weight loss and improved cardiometabolic risk profile in obese rodents (6, 7) and humans (8–11). However, concern over neuropsychiatric side effects, including anxiety, depression, and suicidal ideation (12), prevented approval of the first-in-class CB₁R antagonist rimonabant in the United States and led to its withdrawal from the European market as well as the withdrawal of related compounds from preclinical development (13). Although the exact role of the endocannabinoid system in the control of mood and anxiety-like behaviors is not clear, CB₁R in the prefrontal cortex, amygdala, and the mesolimbic dopaminergic reward pathway have been linked to the control of these behaviors (14). On the other hand, CB₁Rs are also present in peripheral tissues including the liver (15–17), skeletal muscle (18, 19), endocrine pancreas (20, 21), and fat (16, 22, 23), where their activation contributes to obesity-related metabolic and hormonal abnormalities (24–26). This suggests that selective targeting of peripheral CB₁R may result in an improved hormonal-metabolic profile in obesity without the untoward behavioral effects observed following treatment with brain-penetrant CB₁R antagonists. To this end, we have developed a potent, selective, orally bioavailable CB₁R antagonist with limited brain penetrance, and tested its behavioral and metabolic activity profile in two experimental models of obesity as well as in transgenic mice with CB₁R expression limited to the liver. The results indicate that selective targeting of peripheral CB₁R has value in the management of cardiometabolic risk in obesity.

AM6545 is a non-brain-penetrant neutral CB₁R antagonist. First-generation CB₁R antagonists, such as rimonabant, are highly lipid soluble and readily penetrate the blood-brain barrier. In order to reduce brain penetrance, we introduced several modifications into the structure of rimonabant. The analog AM6545 [5-(4-[4-cyanobut-1-ynyl]phenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1,1-dioxo-thiomorpholino)-1H-pyrazole-3-carboxamide] (Figure 1A) is less lipid soluble than rimonabant (estimated partition coefficient [log P], 3.3 vs. 6.4 for rimonabant) but retains high affinity and selectivity for CB₁R. In radioligand displacement assays, AM6545 has a K_I of 3.3 nM for CB₁R, which is similar to that of rimonabant, and greater than 100-fold CB₁/CB₂ selectivity (Figure 1B). Unlike rimonabant, AM6545 does not reduce GTPγS binding in mouse brain membranes and is therefore a neutral antagonist (Figure 1B). Importantly, AM6545 displays markedly reduced brain penetrance, as reflected by a brain/plasma concentration ratio of 0.03 following acute parenteral or oral administration and removal of intravascular fluids, as compared with a ratio of 0.8 for rimonabant (Figure 1C). Brain and plasma levels were also measured 12 hours after dose administration, following chronic (28 days) treatment. The brain/plasma ratio of AM6545 remained low (i.e., 0.07), and the brain concentration of rimonabant continued to be much higher (approximately 14-fold) than that of AM6545 (Figure 1D).

Figure 1

Chemical structure and pharmacological profile of AM6545. (A) Chemical structure of AM6545 and rimonabant. (B) In vitro interaction of antagonists with CB₁R and CB₂R: Left: K_I values for CB₁R (AM6545: 3.3 ± 0.8 nM, rimonabant: 2.9 ± 1.5 nM) and CB₂R (AM6545: 624 ± 128 nM) were derived from displacement of [³H]CP-55,940 binding in mouse brain plasma membranes and membranes of HEK293 cells transfected with mouse CB₂R, respectively. Right: Agonist effect of HU-210, neutral antagonism by AM6545 (AM), and inverse agonism by rimonabant (Rimo), indicated by increase, no change, and decrease in GTPγS binding, respectively. Data represent percentage of stimulation over basal binding and are mean ± SEM of 3 assays performed in triplicate. (C) Concentration of AM6545 and rimonabant in plasma, brain, and liver, 1 hour after i.p. or po administration by gavage of a dose of 10 mg/kg. Data represent mean ± SEM from 3 mice per group. *P < 0.0001 relative to rimonabant. (D) Brain and plasma concentration of AM6545 and rimonabant 12 hours after dose administration, following daily i.p. dosage at 10 mg/kg for 28 days. Data represent mean ± SEM from 3 mice per group. *P < 0.04 relative to rimonabant. (E) Brain and plasma concentrations of AM6545 in Mdr1a/b^–/– and Mdr1a/b^–/–Bcrp^–/– mice and their wild-type (FVB) controls 1 hour after acute i.p. administration of 10 mg/kg AM6545. Note the dramatic increase in brain levels of AM6545 in the knockout strains relative to wild-type controls. Data represent mean ± SEM from 3 mice per group. *P < 0.01 relative to wild-type controls.

In both cell-based and in vitro biochemical assays, AM6545 interacts at low micromolar concentrations with the ABC transporter P-glycoprotein (P-gp; Abcb1), which is localized on the luminal surface of capillary endothelial cells in the brain forming the blood-brain barrier (27) (Supplemental Figure 1; supplemental material available online with this article; doi: 10.1172/JCI42551DS1). This suggests that transporter-mediated extrusion of AM6545 from the brain may contribute to its low apparent brain penetrance. This was further verified in P-gp–deficient (Mdr1a/b^–/–) mice and in mice deficient in both P-gp and Bcrp/Abcg2, along with their wild-type controls. As shown in Figure 1E, brain penetrance of AM6545 increased dramatically in both knockout strains, resulting in brain/plasma ratios of 0.64 and 0.69, respectively. This indicates that the low brain penetrance of AM6545 in wild-type mice is due predominantly to active extrusion by P-gp. Furthermore, when tested in Caco-2 intestinal epithelial cell monolayers (28), AM6545 displays high permeability, with no evidence for active efflux (efflux ratio of 1.1). This suggests good oral bioavailability, also supported by similar plasma concentrations following i.p. and oral administration (Figure 1C).

AM6545 is inactive in behavioral paradigms. We next tested whether the reduced brain penetrance of AM6545 is associated with an attenuation of behavioral effects. Of the cannabinoid-induced behavioral tetrad (29), analgesia is known to have an important peripheral component (30). We therefore compared the effects of AM6545 and rimonabant in antagonizing cannabinoid-induced catalepsy, hypomotility, and hypothermia. Cannabinoid-induced catalepsy, quantified by the bar assay, is mediated exclusively by central CB₁R (31). The marked increase in immobility induced in mice by the cannabinoid agonist HU-210 (30 μg/kg, i.p.) was completely blocked by rimonabant (10 mg/kg, i.p.) but was unaffected by a similar dose of AM6545 (Figure 2A). Similarly, rimonabant completely prevented the hypomotility induced by either i.p. or intracerebroventricular (i.c.v.) administration of the cannabinoid WIN55,212-2, whereas AM6545 at the same dose was without effect (Figure 2B). The hypothermic response to WIN55,212-2 was maximal following an i.c.v. dose of 30 μg or an i.p. dose of 10 mg/kg. The response to the centrally administered agonist peaked at 30 minutes and returned to baseline within 2 hours, and it was completely blocked by pretreatment with 10 mg/kg rimonabant i.p. but was unaffected by the same dose of AM6545 (Figure 2C). The hypothermia was more profound after peripheral as compared with central administration of WIN55,212-2 and lasted up to 8 hours. This effect was again completely blocked by rimonabant, 10 mg/kg, i.p., and was partially inhibited by AM6545, with the residual response being similar in magnitude and duration to the control response to centrally administered WIN55,212-2 (Figure 2C). These findings suggest that both central and peripheral sites contribute to the hypothermic response to WIN55,212-2 and that AM6545 does not affect hypothermia mediated via central CB₁R.

Figure 2

Behavioral activity profile of AM6545 and rimonabant. (A) Rimonabant, but not AM6545, inhibits HU-210–induced catalepsy, as measured by the bar assay. The antagonists (10 mg/kg, i.p.) were given 15 minutes prior to the i.p. injection of 30 μg/kg HU-210. Data represent mean ± SEM from 5 mice per group. *P < 0.001 relative to corresponding value in the absence of HU-210. (B) Rimonabant, but not AM6545, blocks hypomotility induced by WIN55,212-2 administered i.c.v. (30 μg) or i.p. (10 mg/kg), as measured by disruption of infrared xy beams. Data represent mean ± SEM from 6–8 mice per group. *P < 0.009 relative to corresponding vehicle (Veh) value. (C) Rimonabant (10 mg/kg, i.p.) blocks the hypothermic response to WIN55,212-2 administered either i.c.v. (30 μg, left panel) or i.p. (10 mg/kg, right panel), whereas AM6545 (10 mg/kg, i.p.) does not affect the centrally induced response and partially inhibits the peripherally induced hypothermic response to WIN55,212-2. Data represent mean ± SEM from 4–8 mice per group. Where error bars are absent, they are within the symbol. (D) Rimonabant, but not AM6545, increases ambulatory activity. Disruption of infrared xy beams following administration of AM6545 (top) or rimonabant (middle) in wild-type mice or rimonabant in CB1R^–/– mice (10 mg/kg, i.p. each, bottom). Data represent mean ± SEM from 4–6 mice per group. *P < 0.01 relative to corresponding vehicle value. (E) Rimonabant, but not AM6545 (each at 10 mg/kg, i.p.), has an anxiogenic effect in the EPM. Data represent mean ± SEM from 8 mice per group. *P < 0.03 relative to vehicle.

Rimonabant, but not AM6545 (each at 10 mg/kg, i.p.), also induced a marked and long-lasting increase in ambulatory activity in wild-type but not CB1R^–/– mice (Figure 2D). Interestingly, when tested in the P-gp–deficient Mdr1a/b^–/– and Mdr1a/b^–/–abcg2^–/– mice, 10 mg/kg AM6545 caused a robust increase in ambulatory activity similar to rimonabant, reflecting its increased brain penetrance in these mice (Supplemental Figure 2). Similarly, rimonabant but not AM6545 (each at 10 mg/kg, i.p.) induced a robust anxiogenic response in the elevated plus maze (EPM) paradigm (Figure 2E). Thus, AM6545 is devoid of the centrally mediated behavioral effects that are predictive of the neuropsychiatric side effects of brain-penetrant CB₁R antagonists. In contrast, 10 mg/kg AM6545 completely blocked the anandamide-induced inhibition of upper gastrointestinal motility, an effect mediated by prejunctional CB₁R in peripheral neurons innervating the gut (32) (Supplemental Figure 3). Because the dose of anandamide used (10 mg/kg, i.p.) was reported to be maximally effective in this paradigm (33), CB₁R occupancy by AM6545 can be assumed to be near maximal at the 10 mg/kg dose used in most of our experiments.

AM6545 improves the metabolic profile in mice with diet-induced obesity. The metabolic profile of AM6545 and rimonabant was next examined in mice with diet-induced obesity (DIO). Male C57BL/6J mice fed a high-fat diet (HFD) for 14 weeks became obese and were then started on daily i.p. injections of vehicle, rimonabant, or AM6545 (both at 10 mg/kg/d) for an additional 28 days. Age- and sex-matched mice on standard chow served as controls. The overweight and increased adiposity of mice on HFD were significantly reduced by both antagonists (Figure 3, A and B). HFD-induced fatty liver, as reflected in elevated hepatic triglyceride (TG) content, and hepatocellular damage, as indicated by increased plasma ALT levels, were completely reversed by either rimonabant or AM6545 (Figure 3, C and D). Similar effects were observed after oral administration of AM6545 at 10 or 30 mg/kg/d for 14 days (Supplemental Figure 4), indicating good oral bioavailability.

Figure 3

Metabolic effects of chronic treatment with AM6545 and rimonabant in DIO mice. Mice on STD or HFD for 14 weeks were treated with 10 mg/kg/d, i.p., of either drug for 28 days. Note that both drugs reduced body weight (A), adiposity index (B), plasma ALT (C), and hepatic TG (D). Data represent mean ± SEM from 8–12 mice per group from 3 experiments. *P < 0.0001 relative to vehicle group on STD; ^#P < 0.0001 relative to vehicle group on HFD. (E) AM6545 induces CB₁R-dependent reduction in RQ by decreasing CHO and increasing fat oxidation in wild-type mice on STD or on HFD. Indirect calorimetry over a 24-hour period: shaded area indicates lights off; arrows mark time of injection of vehicle (open symbols) or AM6545 (filled symbols). Note the absence of sustained effect of AM6545 in CB1R^–/– mice on regular chow (middle panel). (F) Effects of rimonabant, 10 mg/kg, i.p., on substrate utilization and RQ are similar to those of AM6545. Data represent mean ± SEM from 4 mice per group.

The effect of AM6545 on substrate utilization was analyzed by indirect calorimetry. In mice kept on standard chow, a bolus i.p. dose of 10 mg/kg AM6545 at the start of the light period caused a marked and sustained reduction in respiratory quotient (RQ), resulting from an increase in fat oxidation and decrease in carbohydrate oxidation (CHO) (Figure 3E), which were similar to the effects of rimonabant (Figure 3F). Only transient effects were seen in CB1R^–/– mice (Figure 3E), indicating that the sustained changes were due to CB₁R blockade. Similar effects of AM6545 were seen in mice on HFD, although they were smaller than in mice on standard diet, possibly due to the diet-induced decrease in basal levels of RQ and increase in fat oxidation (Figure 3E). Nevertheless, chronic (28 days) treatment of mice on HFD resulted in increased total energy expenditure in the case of both antagonists (Supplemental Figure 5). Thus, the modest decrease in body weight by AM6545 was probably due to increased lipid oxidation.

This is further indicated by the decreased gene expression of the lipogenic enzymes fatty acid synthase (FAS) and stearoyl coenzyme-A desaturase 1 (Scd1) in both subcutaneous and visceral adipose tissue, whereas the expression of the lipolytic enzyme hormone-sensitive lipase (HSL) was increased in subcutaneous and decreased in visceral fat (Figure 4, A and C), similar to the reported effects of rimonabant (16). Decreased lipogenic and increased lipolytic gene expression was also evident in the liver of DIO mice, where AM6545 treatment resulted in decreased Scd1, FAS, and acetyl coenzyme A carboxylase-1 (Acaca) and increased carnitine palmitoyl transferase–1 (CPT1) expression (Figure 4E). In agreement with the reduced lipogenic gene expression, AM6545 blocked cannabinoid-induced de novo lipogenesis in vitro in isolated mouse hepatocytes (Supplemental Figure 6). AM6545 treatment also reduced CB1R expression in both adipose tissue and liver (Figure 4, A, C, and E), which is again similar to recent findings with rimonabant (16).

Figure 4

Effect of AM6545 on subcutaneous (inguinal) and visceral (epididymal) white adipose tissue (scWAT and viscWAT) and liver mRNA expression of CB1R and genes involved in lipid metabolism. (A, C, and E) DIO mice were on HFD for 14 weeks before treatment with 10 mg/kg/d, i.p., of AM6545 or vehicle for an additional 28 days. (B, D, and F) ob/ob mice on STD received the same daily dose of AM6545 for 28 days. Tissue samples were processed and mRNA levels were determined by real-time PCR as described in Methods. Data are mean ± SEM from 4 mice per condition. *P < 0.05 relative to vehicle group on HFD.

The greater efficacy of rimonabant over AM6545 in reducing body weight is probably related to its additional ability to reduce total caloric intake (Supplemental Figure 7A). A smaller and more transient reduction in food intake by AM6545 did not affect total caloric intake over the treatment period (Supplemental Figure 7B). Nevertheless, to test whether the transient reduction in food intake may contribute to metabolic changes induced by short-term CB₁ antagonist treatment, the effects of treating DIO mice with 10 mg/kg/d AM6545 for 7 days were compared with the effects of pair feeding. As illustrated in Figure 5, short-term AM6545 treatment caused significant reductions in caloric intake, body weight, blood glucose and insulin levels, serum ALT, and hepatic TG content; normalized the impaired glucose tolerance; and improved insulin sensitivity relative to that in free-feeding, vehicle-treated mice. In the pair-fed group, food intake was held at the same reduced level as in AM6545-treated mice, yet all other parameters were similar to those in vehicle-treated controls. Thus, the transient reduction of caloric intake by AM6545 does not contribute to its metabolic effects.

Figure 5

Metabolic effects of short-term treatment with AM6545 or pair feeding in DIO mice. Mice on HFD for 14 weeks were treated with AM6545 (10 mg/kg, i.p.) or vehicle for 7 days. Pair-fed mice were injected with vehicle and fed the same amount as consumed by the AM6545-treated animals over the preceding day. Note that food intake was inhibited only for a short time (B), and only AM6545 reduced body weight (A), blood glucose (C), insulin (D), serum ALT (G), and hepatic TG (H) levels and normalized the impaired glucose tolerance (E) and insulin resistance (F) relative to vehicle treatment under ad libitum (ad. lib.) conditions. Data are mean ± SEM from 4 mice per condition. *P < 0.05 relative to vehicle group on HFD.

In addition to reducing hepatic lipogenesis and increasing fatty acid oxidation, AM6545 treatment also resulted in a marked increase in the hepatic production and release of TG-rich VLDL, as measured in tyloxapol-treated DIO mice (Figure 6). All of these effects could contribute to the reduction of hepatic steatosis.

Figure 6

VLDL-TG secretion rates in DIO and ob/ob mice. Adult DIO and ob/ob mice were treated with 10 mg/kg/d, i.p., of AM6545 or vehicle for 7 days. TGSRs were determined under fasting conditions from the plasma TG versus time curve after the injection of Triton WR-1339, as described in Methods. (A) Plasma TG accumulation over time after Triton WR-1339 administration (500 mg/kg, i.p.) (B) AM6545-induced increase in TGSR (μmol/kg/h) in DIO and ob/ob mice. Data are mean ± SEM from 6 mice per group. *P < 0.05 relative to corresponding vehicle value.

A key component of the obesity-related metabolic syndrome is insulin resistance, which manifested in the simultaneous presence of hyperglycemia and hyperinsulinemia (Figure 7, A and B). DIO mice also displayed hyperleptinemia (Figure 7C), an indication of leptin resistance, whereas the plasma level of adiponectin, an adipokine that promotes fatty acid oxidation, was reduced (Figure 7D). All of these changes were attenuated or completely reversed by CB₁R blockade, rimonabant being somewhat more efficacious than AM6545. DIO mice also displayed reduced glucose tolerance (Figure 7E) and moderately decreased sensitivity to the hypoglycemic effect of insulin (Figure 7F). The reduced glucose tolerance, reflected by the increase in AUC from 327 ± 24 to 437 ± 14 mg/dl/h (P < 0.01) according to the i.p. glucose tolerance test, was reversed to control levels by chronic treatment with either rimonabant (AUC, 279 ± 35 mg/dl/h) or AM6545 (358 ± 14 mg/dl/h). Insulin resistance, as assessed from the insulin-induced change in the normalized blood glucose values, was increased by the HFD, and this increase was reversed by rimonabant but not by AM6545 treatment of DIO mice. When insulin resistance was assessed by the homeostasis model assessment–insulin resistance (HOMA-IR) method and the insulin sensitivity index, both antagonists significantly improved insulin sensitivity, but the effect of rimonabant was stronger (Supplemental Figure 8).

Figure 7

Effects of rimonabant and AM6545 on the hormonal control of carbohydrate metabolism in mice with DIO. Both rimonabant and AM6545 (10 mg/kg/d, i.p., for 28 days) counteract HFD-induced increases in plasma glucose (A), insulin (B), and leptin (C) and decreases in adiponectin levels (D), and improve diet-induced glucose intolerance (E) and insulin resistance (F). Mice were fed STD or HFD (60% of calories from fat) for 14 weeks. Glucose tolerance was tested following the i.p. injection of 2 g/kg glucose. After 2 hours, the mice received 0.75 mU/g insulin i.p. Data represent mean ± SEM from 8–12 mice per group. *P < 0.0001 relative to vehicle group on STD; ^#P < 0.001 relative to vehicle group on HFD.

Weight-independent metabolic effects of AM6545 in leptin-deficient obese mice. In order to test whether peripheral CB₁R blockade affects metabolic parameters in more than one model of obesity, we used genetically leptin-deficient ob/ob mice that develop extreme obesity associated with diabetes, fatty liver, and dyslipidemias. Treatment end points were determined at 7 as well as at 28 days to gain insight into the time course of their development. Daily treatment of adult male ob/ob mice for 7 days with 10 mg/kg of either AM6545 or rimonabant had no significant effect on body weight and adiposity index (Figure 8A), yet both antagonists significantly improved glucose tolerance and insulin resistance (Figure 8B) and reduced the elevated levels of plasma glucose and insulin, with AM6545 being somewhat more effective than rimonabant (Figure 8C). AM6545, but not rimonabant, also markedly lowered liver TG content and reduced hepatocellular damage, as reflected by the lowering of plasma levels of ALT (Figure 8D), whereas after 28 days of treatment, both antagonists were effective in reducing hepatic TG content (Supplemental Figure 9C). AM6545, but not rimonabant, increased HDL cholesterol, and both antagonists reduced LDL cholesterol levels. Plasma TG markedly increased after 7 days of treatment with AM6545, probably as a result of the rapid and robust clearance of liver TGs (Figure 8E). Indeed, AM6545 treatment caused an increase in VLDL-TG production in ob/ob mice similar to that observed in DIO mice (Figure 6).

Figure 8

Effects of short-term CB₁R blockade on hormonal and metabolic parameters in ob/ob mice. Treatment of ob/ob mice with 10 mg/kg/d, i.p., of rimonabant or AM6545 for 7 days does not affect body weight and adiposity (A), but improves glucose tolerance and insulin resistance (B) and reduces plasma glucose and insulin levels (C). AM6545, but not rimonabant, reduces liver TG content and plasma ALT levels (D). Effects of rimonabant and AM6545 on plasma TG and on HDL and LDL cholesterol levels (E). Data represent mean ± SEM from 6 mice per group. *P < 0.05 relative to corresponding vehicle value.

In ob/ob mice treated for 28 days, rimonabant, but not AM6545, caused a modest but significant reduction in body weight and adiposity, and both compounds improved dyslipidemia by reducing plasma TGs and LDL cholesterol levels and increasing plasma HDL cholesterol (Supplemental Figures 9 and 10).

AM6545 treatment improves leptin sensitivity. The ability of AM6545 treatment to reduce body weight and adiposity in DIO mice but not in leptin-deficient ob/ob mice suggests that AM6545 treatment may sensitize adipose tissue to the lipolytic effects of endogenous leptin. Indeed, the AM6545-induced changes in lipogenic gene expression were completely absent in both subcutaneous and visceral adipose tissue of similarly treated ob/ob mice (Figure 4, B and D). In contrast to adipose tissue, lipogenic gene expression in the liver was similarly reduced by AM6545 in DIO and ob/ob mice (Figure 4, E and F). AM6545 also reversed the HFD-induced loss of the appetite-suppressing effect of leptin (Supplemental Figure 11).

Blockade of hepatic CB₁R improves glucose tolerance and reduces hepatic TGs. Selective deletion of CB₁R in hepatocytes has been shown to protect mice from HFD-induced glucose intolerance and insulin resistance and to attenuate the associated steatosis, which implicates endocannabinoids acting via hepatic CB₁R in these processes (24). We generated mice transgenically expressing CB₁R in hepatocytes on a global CB₁R-knockout and C57BL/6J background (htgCB1R^–/– mice) by injecting a DNA construct containing the mouse albumin promoter and the CB₁R coding region into homozygous CB1R^–/– oocytes from superovulated donors. CB1R^–/– mice heterozygous for the transgene and their CB1R^–/– littermates were used to test whether activation of hepatic CB₁R is sufficient to induce diet-induced glucose intolerance/insulin resistance and hepatic steatosis and whether their blockade may contribute to the improved glucose tolerance following short-term treatment with a peripheral CB₁R antagonist. htgCB1R^–/– mice were viable and displayed no gross defects or obvious functional abnormalities. Similar to their global CB1R^–/– littermates, they did not express CB₁R in extrahepatic tissues, including the brain, but had both CB1R mRNA and protein present in hepatocytes at levels somewhat higher than those in wild-type C57BL/6J mice (Figure 9A). Exposure of htgCB1R^–/– mice to HFD resulted in a much smaller, though significant, elevation of hepatic TG levels relative to those of wild-type mice on HFD, whereas no such change was observed in their CB1R^–/– littermates (Figure 9B). In contrast, the robust HFD-induced glucose intolerance and reduced insulin sensitivity in htgCB1R^–/– mice (Figure 9C) were similar to those reported earlier in wild-type mice, as opposed to CB1R^–/– mice, which remain insulin sensitive (34). HFD also resulted in the activation of the ER stress response in the liver as indicated by increased phosphorylation of eukaryotic translation initiation factor 2α (eIF2α) (Figure 9D), a process that has been linked to insulin resistance (35). Furthermore, daily treatment of htgCB1R^–/– mice on HFD for 7 days with 10 mg/kg AM6545, but not with vehicle, reversed all the above diet-induced changes (Figure 9).

Figure 9

Blockade of hepatic CB₁R by AM6545 reverses diet-induced insulin resistance. (A) CB₁R expression in htgCB1R^–/– mice is limited to hepatocytes. CB1R mRNA (top) and protein (bottom) are visualized by RT-PCR and Western blotting, respectively, in brain and liver tissue from wild-type, CB1R^–/–, and htgCB1R^–/– mice. For details, see Methods. (B) Chronic treatment with AM6545 (10 mg/kg/d for 7 days) reduces hepatic TG in wild-type and htgCB1R^–/– but not in CB1R^–/– mice on HFD. Data represent mean ± SEM from 6 mice per group. *P < 0.05 compared with corresponding vehicle value; ^†P < 0.05 compared with corresponding value in CB1R^–/– mice. (C) htgCB1R^–/– mice were kept on STD or HFD for 20 weeks. Mice were then treated with vehicle or AM6545 (10 mg/kg, i.p.) for 7 days and, after overnight fasting, were subjected to an ipGTT (left) followed by ipITT (right). *P < 0.05 compared with corresponding values in vehicle-treated, STD-fed mice. Note the marked glucose intolerance of vehicle-treated mice on HFD relative to both AM6545-treated mice on HFD or the control group on STD (AUC, 426 ± 19 versus 156 ± 6 or 165 ± 47, respectively, n = 6, *P < 0.05). Data represent mean ± SEM from 6 mice per group. (D) Blockade of hepatic CB₁R reverses the HFD-induced ER stress response, as indicated by the phosphorylation state of eIF2α.

Here we have demonstrated that treatment of obese mice with a peripherally restricted CB₁R antagonist improves glycemic control and dyslipidemia and reverses hepatic steatosis, which strongly supports the contribution of peripheral CB₁R activation to these hormonal/metabolic abnormalities. In the absence of any change in body weight in ob/ob mice treated with AM6545, the observed improvements in metabolic parameters were clearly weight independent. In mice with DIO, AM6545 did reduce body weight, but it was less efficacious than the brain-penetrant CB₁R antagonist rimonabant. This is in agreement with the widely held notion that weight reduction by global CB₁R blockade is the combined result of a centrally mediated decrease in caloric intake and a peripherally mediated increase in energy expenditure (11, 36). Indeed, rimonabant, but not AM6545, reduced total caloric intake during the 4-week treatment period, most likely through blockade of CB₁R in the brain (37), and selective blockade of peripheral CB₁R by AM6545 in DIO mice was associated with increased total energy expenditure due to increased fat burning (Figure 3E and Supplemental Figure 5). These metabolic effects of AM6545 were fully evident as early as after 7 days of treatment and were not replicated by pair feeding (Figure 5), which rules out the role of the transient reduction in food intake by AM6545 as their cause.

A likely target of AM6545 is CB₁R in adipocytes, blockade of which results in increased adiponectin secretion (23). AM6545 treatment reversed the diet-induced suppression of plasma adiponectin (Figure 7D), which probably contributed to the observed increase in fat oxidation. The rise in adiponectin could also contribute to the alleviation of hepatic insulin resistance (38). Blocking adipocyte CB₁R may also directly inhibit lipogenesis by decreasing the gene expression of the lipogenic enzymes Scd1 and FAS in adipose tissue of AM6545-treated DIO mice (Figure 4, A and C). Interestingly, AM6545 increased HSL expression in subcutaneous fat but decreased it in visceral fat, similar to the reported effects of rimonabant in DIO mice (16). Although we found that the reduction in adipose tissue mass by AM6545 was similar in the two types of fat tissue (data not shown), the differential regulation of HSL expression may reflect qualitative differences in the effects of endocannabinoids on subcutaneous and visceral adipose tissue.

A possible alternative target of AM6545 in adipose tissue is presynaptic CB₁R on sympathetic nerve terminals, stimulation of which will inhibit norepinephrine release (39). Adipocytes produce and secrete endocannabinoids (40) that could tonically activate such receptors. Rimonabant has been shown to increase norepinephrine turnover in peripheral tissues of wild-type mice but not mice that lack CB₁R in forebrain and sympathetic neurons (41), which makes the above mechanism plausible. The role of such presynaptic CB₁R is compatible with recent findings that hypothalamic leptin suppresses anandamide in white adipose tissue, and when this suppression of endocannabinoid tone is prevented by systemic CB₁R activation or by sympathetic denervation of fat pads, leptin fails to suppress adipose tissue lipogenesis (42). Regardless of the specific cellular target of CB₁R antagonists in adipose tissue, the above-described effects of AM6545 reinforce recent indirect evidence for a partially peripheral mechanism for the reduction of body weight and adiposity by brain-penetrant CB₁R antagonists (11, 26, 43, 44).

The differential effectiveness of AM6545 in reducing body weight and adiposity in DIO mice but not in ob/ob mice may be related to leptin. DIO is known to trigger a primarily peripheral form of leptin resistance (45, 46), which is reflected in a compensatory increase in plasma leptin levels (6, 15). In turn, the observed reversal of hyperleptinemia by CB₁R antagonists reflects improved leptin sensitivity, analogous to the enhanced leptin sensitivity of CB1R^–/– mice (47). In agreement with the above reports, we found that the acute anorexigenic effect of leptin is reduced in mice on HFD, and this reduction was reversed following daily treatment with AM6545 for 9 days (Supplemental Figure 11). Leptin is known to promote fatty acid oxidation independently of its effects on food intake through activation of AMP kinase in muscle and adipose tissue (48). This parallels the ability of CB₁R antagonists to increase the activity of the mitochondrial fatty acid oxidative pathway in liver (24) and increased mitochondrial biogenesis in white adipose tissue (49). Thus, sensitization to the metabolic actions of endogenous leptin may contribute to the increase in fat oxidation and secondary weight loss following AM6545 treatment in DIO mice but not in leptin-deficient ob/ob mice. Direct evidence for such a mechanism is provided by the present findings that, in contrast to its effects in DIO mice, AM6545 treatment failed to decrease lipogenic and increase lipolytic gene expression in adipose tissue of ob/ob mice (Figure 4, B and D).

Apart from showing a small increase in hepatic TGs, htgCB1R^–/– mice were largely resistant to HFD-induced steatosis (Figure 9B). Together with earlier findings that indicate partial protection of liver-specific CB1R^–/– mice from HFD-induced steatosis (24), this points to a dominant role for extrahepatic CB₁R in the development of diet-induced fatty liver. Adipose tissue is a likely candidate, as it may provide free fatty acids for hepatic TG synthesis (16). However, the essentially complete and rapid reversal of hepatic steatosis by AM6545, which indicates a dominant role for peripheral CB₁R, may not be due to a simple reversal of the processes that led to its development. Hepatic CB₁Rs are likely involved, as indicated by the AM6545-induced marked increase in TG-rich VLDL secretion, which paralleled the rapid and near complete elimination of excess hepatic TGs. Preferential targeting of hepatic CB₁R was further facilitated by the accumulation of AM6545 in the liver (Figure 1C). In a recent study, treatment of mice with a novel inhibitor of monoglyceride lipase caused an acute increase in hepatic levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) accompanied by a CB₁R-mediated increase in plasma TGs. This was due to reduced TG clearance with no change in TG secretion by either CB₁R agonist or antagonist (25), which is different from the present findings. It is possible, however, that the link between CB₁R and TG secretion requires long-term activation of the hepatic endocannabinoid system, as induced by HFD. The latter, unlike the acute model, is associated with steatosis, upregulation of hepatic CB₁R (15, 16), and elevated hepatic anandamide rather than 2-AG levels (15).

At the 10 mg/kg dose of AM6545 used here, CB₁R occupancy is near maximal, given that the plasma concentration of the drug (approximately 3 μM, Figure 1C) exceeded its K_I by 3 orders of magnitude. A further indication that blockade of peripheral CB₁R is near complete at this dose is that AM6545 completely blocked inhibition of gut motility by a dose of anandamide (10 mg/kg, Supplemental Figure 3) previously shown to be maximally effective in this paradigm (33). Furthermore, no additional reduction of hepatic TGs and tissue damage markers was observed when the dose of AM6545 was increased from 10 to 30 mg/kg (Supplemental Figure 4). The observed absence of behavioral effects is therefore noteworthy, as it suggests that the therapeutic efficacy of AM6545 could be maximized without the risk of neuropsychiatric side effects. In recent clinical trials with brain-penetrant CB₁R antagonists, concern about neuropsychiatric side effects limited the daily dose used to levels that resulted in only partial (approximately 30%) occupancy of CB₁R (8–11, 50), which may have limited their therapeutic efficacy.

Both rimonabant and AM6545 were effective in attenuating obesity-related glucose intolerance and insulin resistance and normalizing the elevated blood glucose and insulin levels. Although in DIO mice, rimonabant was more efficacious than AM6545 in this regard, in ob/ob mice AM6545 was as effective as rimonabant, suggesting that the improved glycemic control is primarily due to blockade of peripheral CB₁R. A similar conclusion is supported by the finding that insulin sensitivity is improved in DIO rats by chronic systemic, but not by i.c.v., administration of rimonabant, even though the two types of treatment had similar effects on food intake (26). CB₁R on hepatocytes is one of the targets of AM6545. Hepatic CB₁Rs play an important role in insulin resistance, as mice with either global or hepatocyte-specific knockout of CB₁R remain insulin sensitive on HFD (24). The present findings using a rescue model in which CB₁Rs are expressed only in hepatocytes indicate that hepatic CB₁Rs are not only necessary, but sufficient to account for the diet-induced glucose intolerance and insulin resistance. When kept on HFD, these transgenic mice develop glucose intolerance and moderate insulin resistance, whereas their global CB₁R-knockout littermates are resistant to these diet-induced changes. Furthermore, AM6545 treatment normalizes glycemic control in the transgenic mice, which directly implicates CB₁R on hepatocytes as a peripheral target for AM6545. Indeed, our recent experiments using euglycemic-hyperinsulinemic clamp indicate that hepatic CB₁Rs play a dominant role in HFD-induced hepatic insulin resistance by increasing hepatic glucose production and inhibiting the antigluconeogenic effect of insulin (J. Liu et al., unpublished observations). The possible additional contribution of CB₁R in skeletal muscle, adipose tissue, and pancreatic β-cells to the effects of AM6545 on glycemic control remains to be explored.

In summary, AM6545 is a novel, peripherally restricted CB₁R antagonist with nanomolar affinity, selectivity for CB₁R, and therapeutically relevant efficacy in reducing weight and improving hormonal/metabolic abnormalities in animal models of obesity. The previously published, peripherally restricted compound URB447 has approximately 100 times lower CB₁R affinity (IC₅₀, 313 nM) and lacks CB₁/CB₂ selectivity (51), and another recently published compound with reduced brain penetrance has similarly low CB₁R affinity (159 nM) (52). An article describing another peripherally restricted CB₁R antagonist with nanomolar potency and a high degree of selectivity for CB₁ over CB₂ receptors appeared after the present study had been submitted for publication. This antagonist was found to reduce body weight in obese rodents and to inhibit cannabinoid-induced hypothermia only at a high dose, but its metabolic and behavioral profile remains to be established (53).

The absence of neurobehavioral effects of AM6545 similar to those observed with rimonabant suggests that AM6545 will have fewer neuropsychiatric side effects in humans. As a neutral CB₁R antagonist, AM6545 is also expected to cause less nausea than inverse CB₁R agonists do (54). Therefore, further testing and development of compounds of this class may be warranted for the pharmacotherapy of the metabolic syndrome.

View Supplemental data

This work was supported by the NIH (intramural funds from the NIAAA to G. Kunos and from the NCI to S.V. Ambudkar, and 2R01 DA007215 to A. Makriyannis). We thank Christoph Buettner for helpful discussions.

Address correspondence to: George Kunos, Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, USA. Phone: 301.443.2069; Fax: 301.480.0257; E-mail: gkunos@mail.nih.gov. Or to: Alexandros Makriyannis, Center for Drug Discovery, Northeastern University, Boston, Massachusetts 02115, USA. Phone: 617.373.4200; Fax: 617.373.7493; E-mail: a.makriyannis@neu.edu.

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J Clin Invest. 2010;120(8):2953–2966. doi:10.1172/JCI42551.

See the related article at Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?.

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.
   View this article via: PubMed CrossRef Google Scholar
2. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. 2008;51(8):1356–1367.
   View this article via: PubMed Google Scholar
3. Di Marzo V, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol. 2009;161(5):715–722.
   View this article via: PubMed Google Scholar
4. Engeli S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54(10):2838–2843.
   View this article via: PubMed Google Scholar
5. Bluher M, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006;55(11):3053–3060.
   View this article via: PubMed CrossRef Google Scholar
6. Ravinet Trillou C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284(2):R345–R353.
   View this article via: PubMed Google Scholar
7. Gary-Bobo M, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007;46(1):122–129.
   View this article via: PubMed CrossRef Google Scholar
8. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet. 2005;365(9468):1389–1397.
   View this article via: PubMed CrossRef Google Scholar
9. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353(20):2121–2134.
   View this article via: PubMed CrossRef Google Scholar
10. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(7):761–775.
    View this article via: PubMed CrossRef Google Scholar
11. Addy C, et al. The acyclic cb1r inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab. 2008;7(1):68–78.
    View this article via: PubMed CrossRef Google Scholar
12. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370(9600):1706–1713.
    View this article via: PubMed CrossRef Google Scholar
13. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov. 2008;7(12):961–962.
    View this article via: PubMed Google Scholar
14. Moreira FA, Lutz B. The endocannabinoid system: emotion, learning and addiction. Addict Biol. 2008;13(2):196–212.
    View this article via: PubMed Google Scholar
15. Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298–1305.
    View this article via: JCI PubMed Google Scholar
16. Jourdan T, Djaouti L, Demizieux L, Gresti J, Verges B, Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010;59(4):926–934.
    View this article via: PubMed CrossRef Google Scholar
17. Xu X, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31–38.
    View this article via: PubMed CrossRef Google Scholar
18. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006;27(1):73–100.
    View this article via: PubMed CrossRef Google Scholar
19. Eckardt K, et al. Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia. 2009;52(4):664–674.
    View this article via: PubMed CrossRef Google Scholar
20. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) oscillation in islet beta–cells via CB1 receptors. Regul Pept. 2008;145(1–3):49–53.
    View this article via: PubMed CrossRef Google Scholar
21. Bermudez-Silva FJ, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 2008;51(3):476–487.
    View this article via: PubMed CrossRef Google Scholar
22. Cota D, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112(3):423–431.
    View this article via: JCI PubMed Google Scholar
23. Bensaid M, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63(4):908–914.
    View this article via: PubMed Google Scholar
24. Osei-Hyiaman D, et al. Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118(9):3160–3169.
    View this article via: JCI PubMed CrossRef Google Scholar
25. Ruby MA, et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci U S A. 2008;105(38):14561–14566.
    View this article via: PubMed CrossRef Google Scholar
26. Nogueiras R, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes. 2008;57(11):2977–2991.
    View this article via: PubMed CrossRef Google Scholar
27. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398.
    View this article via: PubMed Google Scholar
28. van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1(2):175–185.
    View this article via: PubMed CrossRef Google Scholar
29. Martin BR, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav. 1991;40(3):471–478.
    View this article via: PubMed CrossRef Google Scholar
30. Agarwal N, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci. 2007;10(7):870–879.
    View this article via: PubMed CrossRef Google Scholar
31. Dziadulewicz EK, et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem. 2007;50(16):3851–3856.
    View this article via: PubMed CrossRef Google Scholar
32. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. In Pertwee R, ed. Cannabinoids . New York, New York, USA: Heidelberg: Springer Berlin Heidelberg; 2005:573–598.
33. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol. 1997;340(2–3):R7–R8.
    View this article via: PubMed Google Scholar
34. Osei-Hyiaman D, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118(9):3160–3169.
    View this article via: JCI PubMed CrossRef Google Scholar
35. Ozcan U, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004;306(5695):457–461.
    View this article via: PubMed CrossRef Google Scholar
36. Jbilo O, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19(11):1567–1569.
    View this article via: PubMed Google Scholar
37. Di Marzo V, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410(6830):822–825.
    View this article via: PubMed CrossRef Google Scholar
38. Watanabe T, et al. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem. 2009;284(3):1803–1812.
    View this article via: PubMed Google Scholar
39. Ishac EJ, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol. 1996;118(8):2023–2028.
    View this article via: PubMed Google Scholar
40. Gonthier MP, et al. Identification of endocannabinoids and related compounds in human fat cells. Obesity (Silver Spring). 2007;15(4):837–845.
    View this article via: CrossRef PubMed Google Scholar
41. Quarta C, et al. CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metabolism. 2010;11(4):273–285.
    View this article via: PubMed CrossRef Google Scholar
42. Buettner C, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med. 2008;14(6):667–675.
    View this article via: PubMed CrossRef Google Scholar
43. Herling AW, et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab. 2007;293(3):E826–E832.
    View this article via: PubMed CrossRef Google Scholar
44. Richey JM, et al. Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. Am J Physiol Endocrinol Metab. 2009;296(6):E1311–E1318.
    View this article via: PubMed CrossRef Google Scholar
45. El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827–1832.
    View this article via: JCI PubMed CrossRef Google Scholar
46. Van Heek M, et al. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest. 1997;99(3):385–390.
    View this article via: JCI PubMed CrossRef Google Scholar
47. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28(4):640–648.
    View this article via: PubMed CrossRef Google Scholar
48. Minokoshi Y, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415(6869):339–343.
    View this article via: PubMed CrossRef Google Scholar
49. Tedesco L, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes. 2008;57(8):2028–2036.
    View this article via: PubMed CrossRef Google Scholar
50. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368(9548):1660–1672.
    View this article via: PubMed Google Scholar
51. LoVerme J, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett. 2009;19(3):639–643.
    View this article via: PubMed Google Scholar
52. Son MH, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond). 2010;34(3):547–556.
    View this article via: PubMed CrossRef Google Scholar
53. Receveur JM, et al. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett. 2010;20(2):453–457.
    View this article via: PubMed CrossRef Google Scholar
54. Sink KS, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology. 2008;33(4):946–955.
    View this article via: PubMed CrossRef Google Scholar
55. Alami M, Ferri F, Linstrumelle G. An efficient palladium-catalysed reaction of vinyl and aryl halides or triflates with terminal alkynes. Tetrahedron Lett. 1993;34(40):6403–6406. .
    View this article via: CrossRef Google Scholar
56. Lan R, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem. 1999;42(4):769–776.
    View this article via: PubMed CrossRef Google Scholar
57. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A. 1999;96(10):5780–5785.
    View this article via: PubMed CrossRef Google Scholar
58. Lan R, et al. Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci. 1999;1(2):E4.
    View this article via: PubMed Google Scholar
59. Griffin G, Atkinson PJ, Showalter VM, Martin BR, Abood ME. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5′-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther. 1998;285(2):553–560.
    View this article via: PubMed Google Scholar
60. Hefner K, Holmes A. Ontogeny of fear-, anxiety- and depression-related behavior across adolescence in C57BL/6J mice. Behav Brain Res. 2007;176(2):210–215.
    View this article via: PubMed Google Scholar
61. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497–509.
    View this article via: PubMed Google Scholar
62. Lopez-Parra M, et al. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res. 2008;49(12):2513–2523.
    View this article via: PubMed Google Scholar
63. Chung J, et al. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci U S A. 2008;105(5):1739–1744.
    View this article via: PubMed CrossRef Google Scholar
64. Moverare-Skrtic S, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity (Silver Spring). 2006;14(4):662–672.
    View this article via: PubMed Google Scholar
65. Liu J, et al. Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J. 2000;346(pt 3):835–840.
    View this article via: PubMed Google Scholar